Welcome to the ePoster Viewing Panel of AICOG 2025

Introduction: Endometriosis is an immune-regulated condition known to alter endometrial function with changes in endometrial gene expression and is linked to the genesis of endometrial progesterone resistance and to specific nuclear proteins, including overexpression of endometrial B-cell CLL/lymphoma 6 (BCL6). Aim and Objectives: To investigate the role of endometrial BCL6 overexpression as a biomarker for subclinical endometriosis and progesterone resistance in women with unidentified recurrent pregnancy loss (uRPL) and unexplained infertility (UI). Methodology: Participants were divided into Control, uRPL, and UI groups, each with 15 participants, based on specific inclusion and exclusion criteria. Endometrial biopsies were performed 7-10 days after the LH surge. BCL6 expression was assessed using an automated staining system and assigned a histological score (HSCORE), with overexpression defined as >1.4. Markers of progesterone resistance included menstrual irregularities, elevated E2 to progesterone ratio, low luteal phase progesterone, and thin endometrium. Laparoscopy confirmed endometriosis in selected cases. Statistical analysis was performed using Chi-square and ANOVA tests. Results: 1.High BCL6 H-scores (?1.4) were significantly associated with endometriosis in both uRPL and UI groups, indicating BCL6 as a potential marker for subclinical endometriosis. 2.Higher BCL6 H-scores correlated with menstrual irregularities, elevated estradiol-to-progesterone ratios, low luteal phase progesterone, and thinner endometrial thickness, suggesting a link with progesterone resistance. 3.Elevated BCL6 H-scores in uRPL and UI patients with confirmed endometriosis further validate its diagnostic role. Conclusion: BCL6 expression is a robust marker of progesterone resistance and subclinical endometriosis, particularly in women with recurrent pregnancy loss (uRPL) or unexplained infertility (UI). Further research should investigate the impact of BCL6-targeted therapies.